Expression and clinical relevance of uPA and ET-1 in non-small cell lung cancer

Chinese Journal of Lung Cancer

Volumn 14, Issue 1, 2011, Pages 49-53

  Jiang, Yanyi ^a,b   Liu, Yizhen ^b   Shi, Zhizhou ^b   Wang, Boshi ^b   Shang, Li ^b   Xu, Xin ^b   Zhang, Shengzhou ^b   Wang, Mingrong ^b  

^a ANHUI NORMAL UNIVERSITY   (China)

^b CANCER HOSPITAL   (China)

Author keywords

ET 1; Immunohistochemistry; Lung neoplasms; Prognosis; uPA

Indexed keywords

ENDOTHELIN 1; UROKINASE;

ADENOCARCINOMA; ARTICLE; DISEASE ASSOCIATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; TISSUE MICROARRAY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; ENDOTHELIN-1; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; UP-REGULATION; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 78751700021     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2011.01.10     Document Type: Article

References (16)

1. Janicke F, Schmitt M, Pache L, et al. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat, 1993, 24(3): 195-208.
2. Kobayashi H, Fujishiro S, Terao T. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Res, 1994, 54(24): 6539-6548.
3. Angenete E, Langenskiold M, Palmgren I, et al. uPA and PAI-1 in rectal cancer - relationship to radiotherapy and clinical outcome. J Surg Res, 2009, 153(1): 46-53.
4. Shin BA, Yoo HG, Kim HS, et al. P38 MAPK pathway is involved in the urokinase plasminogen activator expression in human gastric SNU-638 cells. Oncol Rep, 2003, 10(5): 1467-1471.
5. Pakneshan P, Szyf M, Farias-Eisner R, et al. Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis. J Biol Chem, 2004, 279(30): 31735-31744.
6. Eltze E, Wild PJ, Wulfing C, et al. Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters. Eur Urol, 2009, 56(5): 837-845.
7. Asham E, Shankar A, Loizidou M, et al. Increased endothelin-1 in colorectal cancer and reduction of tumour growth by ET(A) receptor antagonism. Br J Cancer, 2001, 85(11): 1759-1763.
8. Ma Z, Tsuchiya N, Yuasa T, et al. Clinical significance of polymorphism and expression of chromogranin a and endothelin-1 in prostate cancer. J Urol, 2010, 184(3): 1182-1188.
9. Liu YC, Li YH, Zhu SJ, et al. Expression of endothelin, vascular endothelial growth factor and microvessel density in non-small cell lung cancer tissue. Mod Oncol, 2009, 17(10): 1881-1884.
10. Rosano L, Spinella F, Di Castro V, et al. Endothelin-1 is required during epithelial to mesenchymal transition in ovarian cancer progression. Exp Biol Med (Maywood), 2006, 231(6): 1128-1131.
11. Boldrini L, Gisfredi S, Ursino S, et al. Expression of endothelin-1 is related to poor prognosis in non-small cell lung carcinoma. Eur J Cancer, 2005, 41(18): 2828-2835.
12. Astedt B, Holmberg L. Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture. Nature, 1976, 261(5561): 595-597.
13. Dass K, Ahmad A, Azmi AS, et al. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev, 2008, 34(2): 122-136.
14. Yang JL, Seetoo D, Wang Y, et al. Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets. Int J Cancer, 2000, 89(5): 431-439.
15. Konecny G, Untch M, Pihan A, et al. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer. Clin Cancer Res, 2001, 7(6): 1743-1749.
16. Hans G, Deseure K, Adriaensen H. Endothelin-1-induced pain and hyperalgesia: a review of pathophysiology, clinical manifestations and future therapeutic options. Neuropeptides, 2008, 42(2): 119-132.